Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.

Author: , AntinoriAndrea, AvihingsanonAnchalee, BaetenJared M, BrinsonCynthia, Dvory-SobolHadas, MargotNicolas, MolinaJean-Michel, OgbuaguOnyema, RatanasuwanWinai, RheeMartin S, Segal-MaurerSorana, TrottierBenoit, WangHui, WorkowskiKimberly, YazdanpanahYazdan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Lenacapavir, a long-acting HIV-1 capsid inhibitor, demonstrated high rates of virological suppression in adults with multidrug-resistant HIV-1 in a Phase 2/3 clinical trial. Subcutaneous lenacapavir, combined with an optimized background regimen, resulted in 83% of participants achieving undetectable viral load at week 52. Lenacapavir resistance emerged in 9 participants, but 4 were able to resuppress while maintaining lenacapavir use. The study suggests that lenacapavir may be a promising treatment option for multidrug-resistant HIV-1.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Lenacapavir, a first-in-class HIV-1 capsid inhibitor, is in development as a long-acting agent for treating and preventing HIV-1. We aimed to evaluate the efficacy and safety of lenacapavir with an optimised background regimen in adults living with multidrug-resistant HIV-1 up to 52 week...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S2352-3018(23)00113-3

データ提供：米国国立医学図書館（NLM）

Lenacapavir: A Promising New Weapon in the Fight Against Multidrug-Resistant HIV

This phase 2/3 trial evaluates the efficacy and safety of lenacapavir, a novel capsid inhibitor, in combination with an optimized background regimen for treating adults with multidrug-resistant HIV-1. The study found that subcutaneous lenacapavir, administered every 26 weeks, resulted in a high rate of virological suppression in individuals with multidrug-resistant HIV-1, with 83% of participants achieving HIV-1 RNA levels below 50 copies per mL at week 52. The study also assessed the safety of lenacapavir, finding that the most common adverse event was injection site reaction. The study's findings suggest that lenacapavir may be a promising new therapeutic option for individuals with multidrug-resistant HIV-1, offering a long-acting and effective treatment approach.

Hope on the Horizon: A Long-Acting Treatment for Multidrug-Resistant HIV

This study offers a ray of hope for individuals with multidrug-resistant HIV-1, highlighting the potential of lenacapavir as a long-acting and effective treatment option. The study's findings suggest that lenacapavir may offer a significant advance in the management of multidrug-resistant HIV-1, providing a more convenient and potentially more effective treatment approach. The study's findings warrant further research and clinical trials to confirm the long-term efficacy and safety of lenacapavir.

A New Era of Treatment: The Promise of Lenacapavir

This study's findings suggest that lenacapavir may usher in a new era of treatment for multidrug-resistant HIV-1, offering a long-acting and effective alternative to existing therapies. The study's findings highlight the importance of ongoing research and development to address the challenges posed by multidrug-resistant HIV-1 and to provide individuals living with this condition with access to safe and effective treatment options.

Dr. Camel's Conclusion

Imagine a camel traversing a vast desert, facing a persistent enemy in the form of multidrug-resistant HIV. Lenacapavir is like a powerful antidote, capable of neutralizing this formidable foe. This study offers a hopeful glimpse into a future where individuals with multidrug-resistant HIV-1 can experience lasting suppression and improved quality of life.

Date :
  1. Date Completed 2023-08-07
  2. Date Revised 2023-08-10
Further Info :

Pubmed ID

37451297

DOI: Digital Object Identifier

10.1016/S2352-3018(23)00113-3

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.